

Normal immunoglobulin

Essential medicine status

General description

Immunoglobulin therapy, also known as normal human immunoglobulin (NHIG), is the use of a mixture of antibodies (immunoglobulins) to treat primary immunodeficiency and Kawasaki disease.

ATC codes

[J06BA02](#)

Medicine type

Biological agent

EML status history

First added in 1977 ([TRS 615](#)) for [Primary immunodeficiencies](#)

Added in 1977 ([TRS 615](#)) for [Mucocutaneous lymph node syndrome](#)

Removed in 2003 ([TRS 920](#)) for [Primary immunodeficiencies](#)

Removed in 2003 ([TRS 920](#)) for [Mucocutaneous lymph node syndrome](#)

Added in 2007 ([TRS 946](#)) for [Primary immunodeficiencies](#)

Added in 2007 ([TRS 946](#)) for [Mucocutaneous lymph node syndrome](#)

Added in 2023 ([TRS 1049](#)) for [Langerhans cell histiocytosis](#)

Added in 2025 ([TRS 1064](#)) for [Acute inflammatory demyelinating polyneuropathy](#)

Wikipedia

[Normal immunoglobulin](#)

DrugBank

[Normal immunoglobulin \(Immune Globulin Human\)](#)

Recommendations

Section

Human immunoglobulins

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

[Primary immunodeficiencies](#) [Mucocutaneous lymph node syndrome](#) [Langerhans cell histiocytosis](#)

Section

Medicines for Guillain-Barré syndrome

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Indications

[Acute inflammatory demyelinating polyneuropathy](#)